545 related articles for article (PubMed ID: 16886440)
21. Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives.
Watkins WJ; Lemoine RC; Chong L; Cho A; Renau TE; Kuo B; Wong V; Ludwikow M; Garizi N; Iqbal N; Barnard J; Jankowska R; Singh R; Madsen D; Lolans K; Lomovskaya O; Oza U; Dudley MN
Bioorg Med Chem Lett; 2004 Oct; 14(20):5133-7. PubMed ID: 15380214
[TBL] [Abstract][Full Text] [Related]
22. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
23. [Fungi isolated from the vagina and their susceptibility to antifungals].
Macura AB; Skóra M
Ginekol Pol; 2012 Jun; 83(6):433-8. PubMed ID: 22880463
[TBL] [Abstract][Full Text] [Related]
24. Respiratory deficiency enhances the sensitivity of the pathogenic fungus Candida to photodynamic treatment.
Chabrier-Roselló Y; Foster TH; Mitra S; Haidaris CG
Photochem Photobiol; 2008; 84(5):1141-8. PubMed ID: 18248505
[TBL] [Abstract][Full Text] [Related]
25. Silver colloidal nanoparticles: antifungal effect against adhered cells and biofilms of Candida albicans and Candida glabrata.
Monteiro DR; Gorup LF; Silva S; Negri M; de Camargo ER; Oliveira R; Barbosa DB; Henriques M
Biofouling; 2011 Aug; 27(7):711-9. PubMed ID: 21756192
[TBL] [Abstract][Full Text] [Related]
26. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
28. [Comparative action of 8 azole derivatives against Candida albicans: fungistatic action and cytologic study by scanning electron microscopy].
Mallie M; Jouvert S; Bastide M; Montes B; Lebecq JC; Bastide JM
Pathol Biol (Paris); 1988 May; 36(5):575-80. PubMed ID: 3043361
[TBL] [Abstract][Full Text] [Related]
29. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
30. Candida species isolated from different body sites and their antifungal susceptibility pattern: Cross-analysis of Candida albicans and Candida glabrata biofilms.
Cataldi V; Di Campli E; Fazii P; Traini T; Cellini L; Di Giulio M
Med Mycol; 2017 Aug; 55(6):624-634. PubMed ID: 27915303
[TBL] [Abstract][Full Text] [Related]
31. Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006.
Metwally L; Walker MJ; Coyle PV; Hay RJ; Hedderwick S; McCloskey BV; O'Neill HJ; Webb CH; McMullan R
J Infect; 2007 Aug; 55(2):174-8. PubMed ID: 17560655
[TBL] [Abstract][Full Text] [Related]
32. Candida glabrata is unusual with respect to its resistance to cationic antifungal proteins.
Helmerhorst EJ; Venuleo C; Beri A; Oppenheim FG
Yeast; 2005 Jul; 22(9):705-14. PubMed ID: 16034806
[TBL] [Abstract][Full Text] [Related]
33. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole.
Rautemaa R; Richardson M; Pfaller M; Perheentupa J; Saxen H
Scand J Infect Dis; 2008; 40(11-12):904-7. PubMed ID: 18651265
[TBL] [Abstract][Full Text] [Related]
34. Substrates and modulators of the multidrug transporter Cdr1p of Candida albicans in antifungal extracts of medicinal plants.
Kolaczkowski M; Kolaczkowska A; Sroda K; Ramalhete C; Michalak K; Mulhovo S; Ferreira MJ
Mycoses; 2010 Jul; 53(4):305-10. PubMed ID: 19460101
[TBL] [Abstract][Full Text] [Related]
35. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Carlyn CJ; Michelsen PB
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):299-304. PubMed ID: 15893901
[TBL] [Abstract][Full Text] [Related]
36. Changes in the cellular composition of Candida albicans resistant to miconazole.
Sharma S; Khuller GK
Indian J Biochem Biophys; 1996 Oct; 33(5):420-4. PubMed ID: 9029825
[TBL] [Abstract][Full Text] [Related]
37. Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole.
Bruzual I; Riggle P; Hadley S; Kumamoto CA
J Antimicrob Chemother; 2007 Mar; 59(3):441-50. PubMed ID: 17261564
[TBL] [Abstract][Full Text] [Related]
38. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Rautemaa R; Richardson M; Pfaller M; Koukila-Kähkölä P; Perheentupa J; Saxén H
J Antimicrob Chemother; 2007 Oct; 60(4):889-92. PubMed ID: 17704513
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips.
Siopi M; Tsala M; Siafakas N; Zerva L; Meletiadis J
J Clin Microbiol; 2015 Nov; 53(11):3654-9. PubMed ID: 26338855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
